Opportunity
Problem
At least 2.2 billion people suffer from near or distance vision impairment, worldwide. Approximately half of all these cases, at least one billion were preventable or could have been addressed.
Cataracts are the second most significant cause of vision problems, a clouding of the lens that causes blurry vision and is sometimes the precursor to blindness. According to the World Health Organization, cataracts affect approximately 94 million people and cause moderate to severe vision loss in over 80% cases. As populations age and average life expectancy continues to increase worldwide, the number of people with cataracts will continue to grow.
Solution
Individuals with vision impairments experience serious consequences throughout their lives. It is possible to mitigate many of these adverse consequences if individuals have access to high-quality eye care and rehabilitation. Introducing Wavesense Engineering – improving precision and experience with innovative ophthalmic diagnostic tools.
Wavesense’s advanced tools will enhance the ability to provide clinics and surgeons with comprehensive optical and anatomical information about patients’ eyes. In addition to improving the diagnosis of diseases of the eye, this will also help determine the most suitable treatment and surgical plan for patients to achieve the best possible outcome.
Market
Growing populations and longer life expectancies will increase the risk that more people will develop vision impairment. Wavesense are confident that our products will be extremely well received and beneficial to hospitals and eye clinics throughout the European market, initially, with the possibility of expanding worldwide at a later stage.
Company Overview
Research and development have been the focus of Wavesense since its inception. Wavesense generated revenue, in its early years, by assisting a major company involved in the medical device sector. In 2020, Wavesense and the company reached an agreement for non-exclusive licensing (limited to a focus market segment), through which Wavesense raised some initial capital. Current efforts are being made to raise funding for Wavesense’s envisioned ophthalmic diagnostic device.
